




R. Welch, Syracuse University: I will be speaking later and I was worried you were going 
to steal my thunder. You did steal some of it, but hopefully I can add something. I used to 
work for the Foreign Agriculture Service in 1989–91, and we were definitely talking about 
STS and biotech. It was coming down the pike, and the general consensus was STS was 
going to be a very useful tool against you. Everybody thought so. It was definitely on the 
radar and my question is if regulatory regimes aren’t more than just trade barriers? Aren’t 
they also ways for people who want to organize their societies and address their problems? 
So is it impossible to harmonize regulatory regimes across different cultures and societies? 
Kerr: I think it is probably difficult, but I agree with you. I think we have to explore this 
because I do think over the long run the cost of not having some kind of organization 
is very high. 
Schechtman: I will add two quick things: one is that the goal of harmonization with 
the EU is something that maybe we were doing less specifically bilaterally on biotech, 
certainly back in the years you were talking about. We were also not working with the 
expectation that we could harmonize with the EU on this subject. The other is that maybe 
a center for cooperation meant to reach these agreements is not the only venue, there is 
also this whole idea that two countries can agree to the same level of protection. Though 
we have a lot of trouble with the EU on biotech issues, we were able to reach an organic 
equivalency, which doesn’t mean that we necessarily follow exactly the same route, but 
that we are reaching the same place.
R. Roush, Penn State:  The overarching impression I have of the whole panel is that while 
we may break out of this log jam, at least some of us in the audience are aware that various 
anti-GM activists are traveling through the developing world offering biosafety training 
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sessions which are a thinly veiled opportunity for them to make GM crops sound as dan-
gerous as possible. Hundreds of studies have been done in the United States on impacts, 
and repeated in those countries to make sure there couldn’t be any possible differences. 
This is happening all the time in an effort to stir the pot. I came away from listening to 
all three talks asking, what do we really need to do to get international approval? I can 
appreciate what you offer. It is difficult, but something has to be done outside the box 
to try to break this log jam. I am wondering if there are any ideas about this out there.
Giroux: I think more than in the industrial world, in developing countries consumers 
hear positive messages about biotechnology, so it is easier for folks to embrace that tech-
nology. The negative comments on biotechnology are all flowing in the same direction, 
they use those negative comments to influence the discussion. Maybe they haven’t really 
figured it all out. If 1 in 1,000 safety studies says it may not be safe, we in this room as 
scientists recognize that that means nothing, right? The weight of evidence of the other 
999 studies has not been disproved by a single study. The average consumer doesn’t un-
derstand that. They don’t understand the scientific process. So how do we make sure that 
the overwhelming messages going to consumers and national governments are positive 
messages about biotechnology? We need to find ways to minimize negative messages or 
the perception that there is a lot of infighting going on.
R. Roush: To follow that logic would be a bit like going on the Daily Show, so when they 
say that we need to show scientific balance on climate change, we follow two climate 
change skeptics with 98 climate change supporters. You are suggesting that ultimately it 
is still a media battle.
Kerr: Just to follow that up, agriculture and many consumers are actually very willing 
to accept the science.
T. Shelton, Cornell University: I have a specific question for Randall. You mentioned 
biotech traits in the United States in soybeans would cut off trade options elsewhere. 
You are probably aware that Brazil right now is contemplating the release of soybeans 
that have insect resistance, particularly to the soybean looper. Now a lot of people at the 
entomological meeting think this is a very dubious undertaking. There is a question about 
whether Brazilians will be able to manage the resistance potential well by establishing 
refuges and whether the trait is even actually needed to increase production of soybeans 
in Brazil. If they do succeed in adopting this in Brazil, would it mean they will be faced 
with a nontariff trade barrier in Europe the United States won’t have, or will that be the 
loss of the European market?
R. Giroux: First of all it is interesting that a number of our trade partners or trade com-
petitors also require a market impact assessment ahead of that commercialization as part 
of their biotech approval process. I can’t give you any response, I’m just not an expert in 
that area. What I do know is that the Brazilian government and Brazilian agriculture are 
very keen on market access. They are very clear that market access is their number one 
priority. Building Brazilian agriculture, building infrastructure, finding export markets 
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for what is one of their key industries, and so we should anticipate the decisions to make 
sure that those markets remain open for Brazilian farmers.
T. Shelton: We have been talking about what the US is doing to try to prevent these 
damaging situations to US agriculture. You mentioned other countries like Brazil or Chile: 
Are they handling things any differently? Maybe you touched on it by saying they look 
for more premarket approval, but is there a working group with the US and Brazil and 
Argentina and the other GM-producing countries that can work together to try and solve 
this dilemma, or are we just going to have a lot of individual preferential trade agreements?
Giroux: There are two that I am aware of. There is the International Soy Growers Alli-
ance, which represents 95% of the exportable soybeans of the world. Members are the 
US, Canada, Brazil, Argentina, and Uruguay. And they have declared that there be no 
commercialization ahead of key markets. So they are very much aware that in the Western 
Hemisphere market access for soybeans is critical. They don’t accept grain channeling as 
a solution. I understand that therefore they will not commercialize ahead of key markets. 
What is the key market for soybeans? China. So, regardless of how difficult China is as 
a customer, they are THE most important customer for soybeans in the world, and you 
should take advantage of that. There is also a group of maize organizations called Maizol 
which is a collection of corn grower associations, and they struggle with the same issue. 
How do we enable market access for US corn? So there are organizations that are looking 
specifically at this issue of market access. So do we just try to outnumber the EU after a 
while? Vietnam is now producing corn. Indonesia and Malaysia were mentioned. Basi-
cally just try to get a lot of other countries producing it and then outnumber the EU?
T. Shelton: So do we just try to outnumber the EU after a while? Vietman is now produc-
ing corn. Indonesia and Malaysia were mentioned. Should we basically just try to get a 
lot of other countries to produce so as to outnumber the EU? 
Giroux: I don’t think about it that way. I think we just have a collection of customers 
who have specific attributes that they want and we are going to serve those customers. 
And so customers we can serve will become preferential destinations for products. If we 
have predictability, reasonable regulatory expectations, and can move those grains and oil 
seeds, those countries will be preferred over others that are more difficult. And generally 
if they are difficult you are going to have to pay more for what you want.
